AVM Biotechnology Information

View Top Employees from AVM Biotechnology

The company's lead drug AVM0703, a proprietary innovative formulation of dexamethasone, when given at supra-pharmacologic doses has a novel mechanism of action to mobilize the body's own natural supercharged immune cells. AVM0703 triggers the production and release of endogenous gamma delta TCR+ invariant TCR+ bispecific T lymphocytes and Natural Killer T cells and could be the first choice for no-option cancer, autoimmunity, and infectious disease. AVM Biotechnology was founded by Dr. Theresa Deisher with a personal mission to defeat cancer and has a Scientific Advisory Board including well-respected leaders in cancer and immunology. The company is committed to developing products that improve outcomes without additional suffering because side effects from treatments should never be worse than the diseases themselves.

Website	http://www.avmbiotech.com
Revenue	$3 million
Employees	14 (12 on RocketReach)
Founded	2008
Address	1749 Dexter Ave N, Seattle, Washington 98109, US
Phone	+1 206-906-9922
Technologies	JavaScript , HTML , PHP +21 more (view full list)
Industry	Biotechnology Research, Business Services General, Biotechnology, R&D, Business Services, Science and Engineering, Drug Discovery, Medical, Stem Cells, Health Care, Regenerative Medicine, Pharmaceutical, Fully Human Biologics, Personalized Medicine
Keywords	Biotechnology, Drug Development, Life Sciences, Immunotherapy, Drug Discovery, Pharmaceutical, Immune System, Biopharma, Pharmaceutical Research, Biologics, Cancer Treatment, Oncology, Clinical Trials, Precision Medicine, Cell Therapy
Competitors	Roche, Thermo Fisher Scientific, Novartis, GSK, Bristol Myers Squibb, Genentech, Amgen, Biogen, 11th Hour Search LLC, Genomatix AG +45 more (view full list)
SIC	SIC Code 87 Companies, SIC Code 873 Companies
NAICS	NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 54171 Companies